GeneVentiv Therapeutics, Inc.
June 24, 2026
Theater 3
Type: Company Presentation
Focus Area:
Cell and Gene Therapy and Genome Editing
GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on identifying, in-licensing and developing transformative gene therapies. GeneVentiv has two first-in-class gene therapies for patients with significant unmet needs. GENV-HEM is a gene therapy for all hemophilias, including inhibitor patients, and without the durability issues that have plagued Factor VIII gene therapies. GENV-002 is a first-in-class gene editing therapy for both the Infantile Onset (IOPD) and Late Onset (LOPD) forms of Pompe disease that stably integrates a functional GAA transgene offering lifelong enzyme production, something that other gene therapies are unable to achieve. With these gene therapies we can transform the lives of 270,000+ developed world patients.
Company HQ City:
Raleigh
Company HQ State:
NC
Company HQ Country:
United States
Year Founded:
2020
Lead Product in Development:
GENV-HEM (AAV8.FVa) gene therapy expressing activated human Factor V, which can treat patients with hemophilia A with or without inhibitors.
CEO
Damon R. Race
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
Our FDA Pre-IND Meeting will take place in July/August of 2026.
What is your next catalyst (value inflection) update?
GENV-HEM has been administered to hemophilia A dogs in an ongoing study our next value inflection point is an FDA Pre-IND Meeting, which will take place in July/August of 2026. Following that our biodistribution/toxicology study in non-human primates will begin in October/November 2026 to be followed by an IND submission.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}